Talactoferrin fails FORTIS-M trial for NSCLC - 09-Aug-2012

The FORTIS-M trial of talactoferrin from Aggenix AG, investigated the effect of talactoferrin plus best supportive care (BSC) compared with placebo and BSC in patients with Stage IIIb/IV Non Small Cell Lung Cancer, whose disease had progressed following two or more prior treatment regimens. Results showed that median overall survival in the talactoferrin arm was just 7.5 months compared to 7.7 months for placebo, which has brought to an end the development programme .

Related News

Reassessment by IQWiG finds Xalkori (Pfizer) may offer considerable benefit for ALK+ NSCLC

Phase III trial of Alimta (Eli Lilly) fails to meet primary endpoint in NSCLC

Sanofi terminates development of iniparib in NSCLC

Phase III study of Vargatef (Boehringer) meets primary endpoint in patients with NSCLC

Phase III study of Tomtovok (Boehringer) meets endpoint for NSCLC

IDMC halts Phase III study of Vargatef (Boehringer) in NSCLC

FDA approves Tarceva (Genentech/Astellas) for NSCLC as detected by cobas EGFR Mutation Test

NICE rejects Xalkori (Pfizer) for treatment of Non Small Cell Lung Cancer

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

The Effect of Cancer Therapies and Exercise on Mitochondrial Energetics and Fitness

Clinicaltrials.gov 13 May 2013

Randomized Study Comparing Different Chemotherapy + Immune Therapy on the Pathological Response on Metastases From Colorectal Cancer

Clinicaltrials.gov 07 May 2013
View all

Oncology Medical Journal Abstracts

Geriatric Syndromes increased the Nutritional Risk in Elderly Cancer Patients Independently from Tumor Site and Metastatic Status. The ELCAPA-05 Cohort Study.

Clinical Nutrition 05 June 2013

Long-Term Follow Up Reveals Low Incidence of Colorectal Cancer, but Frequent Need for Resection, Among Australian Patients with Inflammatory Bowel Disease

Clinical Gastroenterology and Hepatology 28 May 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Phase III SETTLE trial of safinamide (Newron Pharma) shows significant improvements in Parkinson's...

20 Jun 2013

Results from the SETTLE Phase III study of safinamide, from Newron Pharma, shows it significantly improved "super responder" rates in...

Read full article

FDA investigate two deaths after treatment with Schizophrenia drug Zyprexa Relprevv (Eli Lilly)

20 Jun 2013

Following the deaths of two patients with Schizophrenia who had received intramuscular injections with Eli Lilly's Zyprexa Relprevv...

Read full article

FDA accepts BLA for Rhucin as a treatment for HAE

20 Jun 2013

The FDA has accepted for review the biologic license application (BLA) for Rhucin (recombinant human C1 esterase inhibitor) as a treatment...

Read full article